Baxter International's earnings call highlighted revenue growth in key segments, particularly in Advanced Surgery and Healthcare Systems & Technologies. However, significant challenges exist, notably with the Infusion Therapies and Pharmaceuticals segments, as well as the decision to reduce the dividend for deleveraging purposes. The company's focus on stabilizing business operations, improving the balance sheet, and driving continuous improvement reflects a proactive approach to addressing these challenges.
Company Guidance
During Baxter International's third quarter 2025 earnings call, the company provided updated guidance for both the full year and the fourth quarter of 2025. For the full year, Baxter expects total sales growth of 4% to 5% on a reported basis, with operational sales growth projected at 1% to 2% after excluding foreign exchange impacts and other adjustments. The guidance reflects challenges in certain business segments, such as the Infusion Therapies & Technologies division, due to issues with the Novum IQ Large Volume pump, which is expected to impact sales beyond 2025. Full-year adjusted earnings per share are anticipated to be between $2.35 and $2.40, a revision from the previous forecast. For the fourth quarter, Baxter projects a 2% sales growth on a reported basis and a 2% decline on an operational basis, with adjusted earnings per share estimated at $0.52 to $0.57. These projections take into account various factors, including foreign exchange, tariffs, and the divestiture of the Kidney Care business.
Overall Revenue Growth
Third quarter 2025 global sales from continuing operations totaled $2.8 billion, increasing 5% on a reported basis and 2% on an operational basis.
Advanced Surgery Segment Performance
Sales in Advanced Surgery totaled $306 million and grew 11% globally, reflecting strong demand and commercial execution.
Healthcare Systems & Technologies Segment
Sales in the quarter totaled $773 million, increasing 2%, driven by 4% growth in the U.S. for Care and Connectivity Solutions.
Adjusted Earnings Growth
Adjusted earnings from continuing operations were $0.69 per share for the quarter, increasing 41% versus the prior year.
Baxter International (BAX) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BAX Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Oct 30, 2025
$22.42
$19.16
-14.54%
Jul 31, 2025
$27.85
$21.61
-22.41%
May 01, 2025
$30.78
$30.29
-1.59%
Feb 20, 2025
$30.29
$32.86
+8.48%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Baxter International (BAX) report earnings?
Baxter International (BAX) is schdueled to report earning on Feb 12, 2026, Before Open (Confirmed).
What is Baxter International (BAX) earnings time?
Baxter International (BAX) earnings time is at Feb 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.